Light-activated liposomes coated with hyaluronic acid as a potential drug delivery system

Otto K. Kari; Shirin Tavakoli; Petteri Parkkila; Simone Baan; Roosa Savolainen; Teemu Ruoslahti; Niklas G. Johansson; Joseph Ndika; Harri Alenius; Tapani Viitala; Arto Urtti; Tatu Lajunen

doi:10.3390/pharmaceutics12080763

Light-activated liposomes coated with hyaluronic acid as a potential drug delivery system

Otto K. Kari, Shirin Tavakoli, Petteri Parkkila, Simone Baan, Roosa Savolainen, Teemu Ruoslahti, Niklas G. Johansson, Joseph Ndika, Harri Alenius, Tapani Viitala, Arto Urtti, Tatu Lajunen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Scientific › peer-review

40 Citations (Scopus)

Abstract

Light-activated liposomes permit site and time-specific drug delivery to ocular and systemic targets. We combined a light activation technology based on indocyanine green with a hyaluronic acid (HA) coating by synthesizing HA–lipid conjugates. HA is an endogenous vitreal polysaccharide and a potential targeting moiety to cluster of differentiation 44 (CD44)-expressing cells. Light-activated drug release from 100 nm HA-coated liposomes was functional in buffer, plasma, and vitreous samples. The HA-coating improved stability in plasma compared to polyethylene glycol (PEG)-coated liposomes. Liposomal protein coronas on HA-and PEG-coated liposomes after dynamic exposure to undiluted human plasma and porcine vitreous samples were hydrophilic and negatively charged, thicker in plasma (~5 nm hard, ~10 nm soft coronas) than in vitreous (~2 nm hard, ~3 nm soft coronas) samples. Their compositions were dependent on liposome formulation and surface charge in plasma but not in vitreous samples. Compared to the PEG coating, the HA-coated liposomes bound more proteins in vitreous samples and enriched proteins related to collagen interactions, possibly explaining their slightly reduced vitreal mobility. The properties of the most abundant proteins did not correlate with liposome size or charge, but included proteins with surfactant and immune system functions in plasma and vitreous samples. The HA-coated light-activated liposomes are a functional and promising alternative for intravenous and ocular drug delivery.

Original language	English
Article number	763
Pages (from-to)	1-24
Number of pages	24
Journal	Pharmaceutics
Volume	12
Issue number	8
DOIs	https://doi.org/10.3390/pharmaceutics12080763
Publication status	Published - Aug 2020
Externally published	Yes
MoE publication type	A1 Journal article-refereed

Funding

This research was funded by the Academy of Finland (#311122, #317336), Business Finland (#4208/31/2015), EU Horizon 2020 Marie Sk?odowska-Curie Innovative Training Networks NANOMED project (#676137), Orion Research Foundation (#9-8214-9), Phospholipid Research Center, Emil Aaltonen Foundation, Instrumentarium Science Foundation, Mary and Georg C. Ehrnrooth Foundation, Evald and Hilda Nissi Foundation, Inkeri and Mauri V?nsk? Foundation, Paulo Foundation, and P?ivikki and Sakari Sohlberg Foundation. Open access funding provided by University of Helsinki. Funding: This research was funded by the Academy of Finland (#311122, #317336), Business Finland (#4208/31/2015), EU Horizon 2020 Marie Skłodowska-Curie Innovative Training Networks NANOMED project (#676137), Orion Research Foundation (#9-8214-9), Phospholipid Research Center, Emil Aaltonen Foundation, Instrumentarium Science Foundation, Mary and Georg C. Ehrnrooth Foundation, Evald and Hilda Nissi Foundation, Inkeri and Mauri Vänskä Foundation, Paulo Foundation, and Päivikki and Sakari Sohlberg Foundation. Open access funding provided by University of Helsinki.

Keywords

Biocorona
Drug release
Hyaluronic acid
Light activation
Liposome
Mobility
Stability

Access to Document

10.3390/pharmaceutics12080763

Cite this

@article{b675f69f3ac041b6aec1bd47f7dc7220,

title = "Light-activated liposomes coated with hyaluronic acid as a potential drug delivery system",

abstract = "Light-activated liposomes permit site and time-specific drug delivery to ocular and systemic targets. We combined a light activation technology based on indocyanine green with a hyaluronic acid (HA) coating by synthesizing HA–lipid conjugates. HA is an endogenous vitreal polysaccharide and a potential targeting moiety to cluster of differentiation 44 (CD44)-expressing cells. Light-activated drug release from 100 nm HA-coated liposomes was functional in buffer, plasma, and vitreous samples. The HA-coating improved stability in plasma compared to polyethylene glycol (PEG)-coated liposomes. Liposomal protein coronas on HA-and PEG-coated liposomes after dynamic exposure to undiluted human plasma and porcine vitreous samples were hydrophilic and negatively charged, thicker in plasma (\textasciitilde{}5 nm hard, \textasciitilde{}10 nm soft coronas) than in vitreous (\textasciitilde{}2 nm hard, \textasciitilde{}3 nm soft coronas) samples. Their compositions were dependent on liposome formulation and surface charge in plasma but not in vitreous samples. Compared to the PEG coating, the HA-coated liposomes bound more proteins in vitreous samples and enriched proteins related to collagen interactions, possibly explaining their slightly reduced vitreal mobility. The properties of the most abundant proteins did not correlate with liposome size or charge, but included proteins with surfactant and immune system functions in plasma and vitreous samples. The HA-coated light-activated liposomes are a functional and promising alternative for intravenous and ocular drug delivery.",

keywords = "Biocorona, Drug release, Hyaluronic acid, Light activation, Liposome, Mobility, Stability",

author = "Kari, \{Otto K.\} and Shirin Tavakoli and Petteri Parkkila and Simone Baan and Roosa Savolainen and Teemu Ruoslahti and Johansson, \{Niklas G.\} and Joseph Ndika and Harri Alenius and Tapani Viitala and Arto Urtti and Tatu Lajunen",

note = "Funding Information: This research was funded by the Academy of Finland (\#311122, \#317336), Business Finland (\#4208/31/2015), EU Horizon 2020 Marie Sk?odowska-Curie Innovative Training Networks NANOMED project (\#676137), Orion Research Foundation (\#9-8214-9), Phospholipid Research Center, Emil Aaltonen Foundation, Instrumentarium Science Foundation, Mary and Georg C. Ehrnrooth Foundation, Evald and Hilda Nissi Foundation, Inkeri and Mauri V?nsk? Foundation, Paulo Foundation, and P?ivikki and Sakari Sohlberg Foundation. Open access funding provided by University of Helsinki. Funding Information: Funding: This research was funded by the Academy of Finland (\#311122, \#317336), Business Finland (\#4208/31/2015), EU Horizon 2020 Marie Sk{\l}odowska-Curie Innovative Training Networks NANOMED project (\#676137), Orion Research Foundation (\#9-8214-9), Phospholipid Research Center, Emil Aaltonen Foundation, Instrumentarium Science Foundation, Mary and Georg C. Ehrnrooth Foundation, Evald and Hilda Nissi Foundation, Inkeri and Mauri V{\"a}nsk{\"a} Foundation, Paulo Foundation, and P{\"a}ivikki and Sakari Sohlberg Foundation. Open access funding provided by University of Helsinki. Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2020",

month = aug,

doi = "10.3390/pharmaceutics12080763",

language = "English",

volume = "12",

pages = "1--24",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "MDPI",

number = "8",

}

TY - JOUR

T1 - Light-activated liposomes coated with hyaluronic acid as a potential drug delivery system

AU - Kari, Otto K.

AU - Tavakoli, Shirin

AU - Parkkila, Petteri

AU - Baan, Simone

AU - Savolainen, Roosa

AU - Ruoslahti, Teemu

AU - Johansson, Niklas G.

AU - Ndika, Joseph

AU - Alenius, Harri

AU - Viitala, Tapani

AU - Urtti, Arto

AU - Lajunen, Tatu

N1 - Funding Information: This research was funded by the Academy of Finland (#311122, #317336), Business Finland (#4208/31/2015), EU Horizon 2020 Marie Sk?odowska-Curie Innovative Training Networks NANOMED project (#676137), Orion Research Foundation (#9-8214-9), Phospholipid Research Center, Emil Aaltonen Foundation, Instrumentarium Science Foundation, Mary and Georg C. Ehrnrooth Foundation, Evald and Hilda Nissi Foundation, Inkeri and Mauri V?nsk? Foundation, Paulo Foundation, and P?ivikki and Sakari Sohlberg Foundation. Open access funding provided by University of Helsinki. Funding Information: Funding: This research was funded by the Academy of Finland (#311122, #317336), Business Finland (#4208/31/2015), EU Horizon 2020 Marie Skłodowska-Curie Innovative Training Networks NANOMED project (#676137), Orion Research Foundation (#9-8214-9), Phospholipid Research Center, Emil Aaltonen Foundation, Instrumentarium Science Foundation, Mary and Georg C. Ehrnrooth Foundation, Evald and Hilda Nissi Foundation, Inkeri and Mauri Vänskä Foundation, Paulo Foundation, and Päivikki and Sakari Sohlberg Foundation. Open access funding provided by University of Helsinki. Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2020/8

Y1 - 2020/8

N2 - Light-activated liposomes permit site and time-specific drug delivery to ocular and systemic targets. We combined a light activation technology based on indocyanine green with a hyaluronic acid (HA) coating by synthesizing HA–lipid conjugates. HA is an endogenous vitreal polysaccharide and a potential targeting moiety to cluster of differentiation 44 (CD44)-expressing cells. Light-activated drug release from 100 nm HA-coated liposomes was functional in buffer, plasma, and vitreous samples. The HA-coating improved stability in plasma compared to polyethylene glycol (PEG)-coated liposomes. Liposomal protein coronas on HA-and PEG-coated liposomes after dynamic exposure to undiluted human plasma and porcine vitreous samples were hydrophilic and negatively charged, thicker in plasma (~5 nm hard, ~10 nm soft coronas) than in vitreous (~2 nm hard, ~3 nm soft coronas) samples. Their compositions were dependent on liposome formulation and surface charge in plasma but not in vitreous samples. Compared to the PEG coating, the HA-coated liposomes bound more proteins in vitreous samples and enriched proteins related to collagen interactions, possibly explaining their slightly reduced vitreal mobility. The properties of the most abundant proteins did not correlate with liposome size or charge, but included proteins with surfactant and immune system functions in plasma and vitreous samples. The HA-coated light-activated liposomes are a functional and promising alternative for intravenous and ocular drug delivery.

AB - Light-activated liposomes permit site and time-specific drug delivery to ocular and systemic targets. We combined a light activation technology based on indocyanine green with a hyaluronic acid (HA) coating by synthesizing HA–lipid conjugates. HA is an endogenous vitreal polysaccharide and a potential targeting moiety to cluster of differentiation 44 (CD44)-expressing cells. Light-activated drug release from 100 nm HA-coated liposomes was functional in buffer, plasma, and vitreous samples. The HA-coating improved stability in plasma compared to polyethylene glycol (PEG)-coated liposomes. Liposomal protein coronas on HA-and PEG-coated liposomes after dynamic exposure to undiluted human plasma and porcine vitreous samples were hydrophilic and negatively charged, thicker in plasma (~5 nm hard, ~10 nm soft coronas) than in vitreous (~2 nm hard, ~3 nm soft coronas) samples. Their compositions were dependent on liposome formulation and surface charge in plasma but not in vitreous samples. Compared to the PEG coating, the HA-coated liposomes bound more proteins in vitreous samples and enriched proteins related to collagen interactions, possibly explaining their slightly reduced vitreal mobility. The properties of the most abundant proteins did not correlate with liposome size or charge, but included proteins with surfactant and immune system functions in plasma and vitreous samples. The HA-coated light-activated liposomes are a functional and promising alternative for intravenous and ocular drug delivery.

KW - Biocorona

KW - Drug release

KW - Hyaluronic acid

KW - Light activation

KW - Liposome

KW - Mobility

KW - Stability

UR - https://www.scopus.com/pages/publications/85090256885

U2 - 10.3390/pharmaceutics12080763

DO - 10.3390/pharmaceutics12080763

M3 - Article

AN - SCOPUS:85090256885

SN - 1999-4923

VL - 12

SP - 1

EP - 24

JO - Pharmaceutics

JF - Pharmaceutics

IS - 8

M1 - 763

ER -

Light-activated liposomes coated with hyaluronic acid as a potential drug delivery system

Abstract

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this